The Food and Drug Administration (FDA) published an update to its guidance document titled “Breakthrough Devices Program, Guidance for Industry and Food and Drug Administration Staff” on September 15, 2023. In this revised guidance document, the FDA may consider a medical device’s potential to address health and healthcare disparities when deciding on its categorization as a breakthrough device.
A breakthrough medical device, as outlined by the FDA, is one that may be more effective in treating or diagnosing life-threatening or irreversibly debilitating diseases or conditions. This initiative’s purpose is to expedite the development and review of such medical devices to ensure that patients with vital needs gain access to these innovations quickly.
With this updated guidance, the FDA seems to be emphasizing a broader view of the potential benefit of these devices. The decision to include a device’s ability to improve healthcare disparities suggests a desire to ensure that innovative healthcare technologies are accessible and beneficial to all, regardless of demographics or socio-economic status.
FDA’s considerations might involve examining whether a device can address a health or healthcare disparity that is not successfully treated by the existing state of technology or medical treatments. If a proposed device presents solutions to these challenges, it could witness a faster development and review process.
While it remains to be seen how this shift in policy will directly impact approval numbers for breakthrough device applications, it is clear that the FDA is looking to expand the purview of the program beyond simple effectiveness against specific medical conditions. Instead, it is striving to evaluate the broader societal impact and potential for reducing health inequality in the country.
The details on the updated guidance for breakthrough medical device classification can be found on the FDA website or refer to this analysis by Reed Smith.
The corporate legal teams and professionals interested in FDA regulatory affairs are encouraged to keep abreast of such developments. This widened scope can impact the strategic planning of product development and alter the pace of rolling out new medical devices. Advance preparation will ensure smooth navigation through the complex regulatory waters.